According to “2019 China Acne Treatment Guidance”, over 95% of Chinese are suffering from acne in various degrees. The major product classes predominantly used to treat acne have been available for nearly 40 years.
One key iqvia skin#
According to the prescriptions generated, Winlevi® has been one of the most successful US launches in the topical acne space in the last 15 years.Īcne, a chronic inflammatory skin disease, is one of the most common reasons patients visit a dermatologist. About 10,000 US physicians have prescribed Winlevi® to date.
Winlevi® was launched in the US in November 2021 by Sun Pharma and is already the most prescribed branded topical acne drug in the US based on IQVIA data. It is the first in class topical androgen receptor inhibitor that tackles the androgen hormone component of acne and is the first new mechanism of action in acne approved by the FDA in 40 years. Winlevi ® has been approved by the United States Food & Drug Administration (FDA) as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older.
One key iqvia license#
(SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Kong and Macao (“Greater China”). 53 LRĭublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V. Our Products - Quality, Safety and Adverse EventsĪd hoc announcement pursuant to Art.